Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Circulating CD44 and intercellular adhesion molecule-1 levels in low gradenon-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment
Autore:
Beksac, M; Arat, M; Akan, H; Koc, H; Ilhan, O; Ozcan, M;
Indirizzi:
Ankara Univ, Sch Med, Ibni Sina Hosp, Dept Hematol, TR-06100 Ankara, Turkey Ankara Univ Ankara Turkey TR-06100 Dept Hematol, TR-06100 Ankara, Turkey
Titolo Testata:
CANCER
fascicolo: 7, volume: 89, anno: 2000,
pagine: 1474 - 1481
SICI:
0008-543X(20001001)89:7<1474:CCAIAM>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
SERUM LEVELS; PROGNOSTIC MARKERS; ICAM-1; EXPRESSION; CORRELATE; MALIGNANCIES; DISEASE; VARIANT; ALPHA;
Keywords:
soluble adhesion molecules; CD44; CD54; low grade non-Hodgkin lymphoma; chronic lymphocytic leukemia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Beksac, M Ankara Univ, Sch Med, Ibni Sina Hosp, Dept Hematol, TR-06100 Ankara, Turkey Ankara Univ Ankara Turkey TR-06100 ol, TR-06100 Ankara, Turkey
Citazione:
M. Beksac et al., "Circulating CD44 and intercellular adhesion molecule-1 levels in low gradenon-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment", CANCER, 89(7), 2000, pp. 1474-1481

Abstract

BACKGROUND. Despite published reports regarding the association of elevated circulating CD44 and CD54 levels with unfavorable outcome in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), little is known about therapy-related changes in either adhesion molecule. In an attempt to evaluate the effect of interferon-alpha (IFN alpha), the authors measured serum CD44 (sCD44) and sCD54 in 22 low grade NHL and 14 CU. patients. METHODS, Twenty-six patients fulfilling the criteria for therapy received daily doses of 3 x 10(6) IU IFN alpha-2a. Ten patients not requiring therapy also were observed for the same period. Fasting sera were collected at baseline and in 4 monthly intervals from all patients including the IFN alpha-treated (Group I) and the untreated group (Group 2). RESULTS. Higher baseline sCD44 values were observed in Group 1 as comparedwith the Group 2 patients (P = 0.057). Within Group 1, patients were further divided between those who responded to IFN alpha, referred to as responders, and those who did not respond to IFN alpha, known as nonresponders. Responders showed a gradual decrease in sCD44 starting at the 4th month untilthe 12th month (P = 0.003, P = 0.002, and P = 0.01). Neither a difference in baseline nor an IFN alpha effect on the sCD54 levels could be shown. Soluble CD44 levels between responders and nonresponders were not different atthe baseline but were significantly lower in responders, starting at month4 and continuing throughout the therapy period (P = 0.04, P = 0.017, and P= 0.043). This decrease did not accompany a leukocyte or lactate dehydrogenase decrease and was not correlated with an early disappearance of the clinical findings. Similarly, after treatment, the sCD44 vaIues of Group I were lower than the Group 2 levels at months 4 and 8 (P = 0.007 and P = 0.05, respectively). CONCLUSIONS, soluble CD44, but not sCD54, can be used for monitoring therapy in patients with low grade NHL and CLL who have received IFN alpha, and for deciding whether further IFN therapy is necessary for those patients who have not responded to IFN alpha over a previous 12-month period. Cancer 2000;89:1474-81. (C) 2000 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 09:47:37